Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$6.0 million.

  • Cytosorbents' Other Operating Expenses rose 469.7% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.6 million, marking a year-over-year increase of 1419.59%. This contributed to the annual value of -$16.3 million for FY2024, which is 3613.73% up from last year.
  • Latest data reveals that Cytosorbents reported Other Operating Expenses of -$6.0 million as of Q3 2025, which was up 469.7% from -$5.8 million recorded in Q2 2025.
  • Cytosorbents' 5-year Other Operating Expenses high stood at $1.6 million for Q2 2023, and its period low was -$6.9 million during Q1 2024.
  • Moreover, its 5-year median value for Other Operating Expenses was $609518.0 (2022), whereas its average is -$1.8 million.
  • As far as peak fluctuations go, Cytosorbents' Other Operating Expenses skyrocketed by 13475.59% in 2023, and later plummeted by 127628.74% in 2024.
  • Over the past 5 years, Cytosorbents' Other Operating Expenses (Quarter) stood at $641205.0 in 2021, then rose by 18.3% to $758569.0 in 2022, then tumbled by 548.51% to -$3.4 million in 2023, then rose by 25.5% to -$2.5 million in 2024, then plummeted by 135.55% to -$6.0 million in 2025.
  • Its last three reported values are -$6.0 million in Q3 2025, -$5.8 million for Q2 2025, and -$5.2 million during Q1 2025.